AnaptysBio Inc
ANAB
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.4B
Close$
$-14.56
128.4% downside
Current Fair Value
128.4% downsideOvervalued by 128.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.40 Billion |
|---|---|
| Enterprise Value | $2.43 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.46 |
| Beta | 0.48 |
| Outstanding Shares | 28,691,000 |
Return
| Return on Equity | -210.14% |
|---|---|
| Return on Assets | -8.13% |
| Return on Invested Capital | 10.96% |
Valuation & Multiples
| P/E Ratio | -59.63 |
|---|---|
| PEG | -173 |
| Price to Sales | 6.41 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 10.45 |
| Enterprise Value to EBIT | 76.98 |
| Enterprise Value to Net Income | -91 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 21.76 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$18.86 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$23.98 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2151▼ 131.78% |
|---|---|
| Total Calls | 25,100▼ 91.26% |
| Total Puts | 5,400▼ 98.77% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 152.41%▲ 51.41% |
|---|---|
| Total Invested | $1.55B▲ 8.97% |
| Investors Holding | 209▲ 26.00% |
ESG Score
No data
About AnaptysBio Inc
CEO: Hamza Suria